Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 2, 2002, Pages 444-452

  Lee, Lucille N ^a   Stock, Richard G ^a   Stone, Nelson N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Hormone therapy; Prostate cancer

Indexed keywords

BIOLOGICAL ORGANS; DISEASES; IMPLANTS (SURGICAL); RADIOTHERAPY;

HORMONAL THERAPY;

ONCOLOGY;

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; IODINE 125; LEUPRORELIN; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; RETROSPECTIVE STUDY; SEMINAL VESICLE; SURVIVAL TIME; TECHNIQUE; TREATMENT OUTCOME; TUMOR BIOPSY; ULTRASOUND;

ADULT; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; IODINE RADIOISOTOPES; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLADIUM; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK; TREATMENT FAILURE;

EID: 0036472197     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02598-6     Document Type: Article

References (50)

1. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
2. Prostate specific antigen based disease control following ultrasound guided 125-iodine implantation for stage T1/T2 prostate carcinoma
3. Radiation therapy for T1 and T2 prostate cancer; Prostate-specific antigen and disease outcome
4. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer; Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores
5. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
6. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels
7. Prostate brachytherapy; Treatment strategies
8. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
9. External beam irradiation versus 125 Iodine implant in the definitive treatment of prostate carcinoma
10. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
11. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma; A randomized comparative trial of the Radiation Therapy Oncology Group
12. A dose-response study for I-125 prostate implants
13. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation
14. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate
15. Prostate
16. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate cancer
17. Effect of prognostic factors on therapeutic outcome following perineal prostate brachytherapy
18. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer
19. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection; Implications for patient selection in the radiotherapeutic management of prostate cancer
20. 125I prostate implants; Definitions and factors affecting outcome
21. Dosimetry of interstitial brachytherapy sources; Recommendations of the AAPM Radiation Therapy Committee Task Force Group No. 43
22. Consensus statement; Guidelines for PSA following radiation therapy
23. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer
24. Non parametric estimation from incomplete observations
25. Evaluation of survival data and two new rank order statistics arising is its consideration
26. Regression models and life tables
27. Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer
28. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer
29. Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate
30. Current status of androgen suppression and radiotherapy for patients with prostate cancer
31. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate; experimental and clinical results
32. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy; Report of Radiation Therapy Oncology Group Protocol 85-31
33. Androgen ablation adjuvant to definitive radiotherapy in carcinoma of the prostate; Year 2000 update of RTOG phase III studies 86-10 and 85-31
34. Predicting long-term survival and the need for hormonal therapy; A meta-analysis of RTOG prostate cancer trials
35. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy; A phase III EORTC study
36. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation
37. Identification of intermediate-risk prostate cancer patients treated with radical radiotherapy suitable for neoadjuvant hormone studies
38. RTOG protocol 92-02; A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate
39. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
40. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy
41. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate
42. External beam radiotherapy dose response of prostate cancer
43. Optimization of conformal radiation treatment of prostate cancer; Report of a dose escalation study
44. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer
45. Simultaneous irradiation for prostate cancer; Intermediate results with modern techniques
46. 103Pd brachytherapy and external beam irradiation for clinically localized, high risk prostatic carcinoma
47. High dose combination radiotherapy for the treatment of localized prostate cancer
48. The radial distance of extraprostatic extension of prostate carcinoma
49. A phase I/II trial of neoadjuvant androgen suppression, 3D-conformal external beam irradiation and palladium-103 brachytherapy in the treatment of locally advanced prostate cancer